© 1996 American Heart Association, Inc.
Articles |
Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia
From the Institut National de la Santé et de la Recherche Médicale (INSERM) (M.G., M.J.C.), Unité 321, Pavillon Benjamin Delessert, and the Service d'Endocrinologie-Métabolisme (E.B., G.T.), Hôpital de la Pitié, Paris, France, and The Lipoprotein Group (P.J.D.), Department of Biochemistry, Dalhousie University, Halifax, Nova Scotia, Canada.
Correspondence to Maryse Guérin, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 321, Pavillon Benjamin Delessert, Hôpital de la Pitié, 83 Boulevard de l' Hôpital, 75651 Paris cedex 13, France.
Abstract The effect of fenofibrate on plasma cholesteryl ester transfer protein (CETP) activity in relation to the quantitative and qualitative features of apoB- and apoA-I–containing lipoprotein subspecies was investigated in nine patients presenting with combined hyperlipidemia. Fenofibrate (200 mg/d for 8 weeks) induced significant reductions in plasma cholesterol (-16%; P<.01), triglyceride (-44%; P<.007), VLDL cholesterol (-52%; P=.01), LDL cholesterol (-14%; P<.001), and apoB (-15%; P<.009) levels and increased HDL cholesterol (19%; P=.0001) and apoA-I (12%; P=.003) levels. An exogenous cholesteryl ester transfer (CET) assay revealed a marked decrease (-26%; P<.002) in total plasma CETP-dependent CET activity after fenofibrate treatment. Concomitant with the pronounced reduction in VLDL levels (37%; P<.005), the rate of CET from HDL to VLDL was significantly reduced by 38% (P=.0001), whereas no modification in the rate of cholesteryl ester exchange between HDL and LDL occurred after fenofibrate therapy. Combined hyperlipidemia is characterized by an asymmetrical LDL profile in which small, dense LDL subspecies (LDL-4 and LDL-5, d=1.039 to 1.063 g/mL) predominate. Fenofibrate quantitatively normalized the atherogenic LDL profile by reducing levels of dense LDL subspecies (-21%) and by inducing an elevation (26%; P<.05) in LDL subspecies of intermediate density (LDL-3, d=1.029 to 1.039 g/mL), which possess optimal binding affinity for the cellular LDL receptor. However, no marked qualitative modifications in the chemical composition or size of LDL particles were observed after drug treatment. Interestingly, the HDL cholesterol concentration was increased by fenofibrate therapy, whereas no significant change was detected in total plasma HDL mass. In contrast, the HDL subspecies pattern was modified as the result of an increase in the total mass (11.7%) of HDL2a, HDL3a, and HDL3b (d=1.091 to 1.156 g/mL) at the expense of reductions in the total mass (-23%) of HDL2b (d=1.063 to 1.091 g/mL) and HDL3c (d=1.156 to 1.179 g/mL). Such changes are consistent with a drug-induced reduction in CETP activity. In conclusion, the overall mechanism involved in the fenofibrate-induced modulation of the atherogenic dense LDL profile in combined hyperlipidemia primarily involves reduction in CET from HDL to VLDL together with normalization of the intravascular transformation of VLDL precursors to receptor-active LDLs of intermediate density.
Key Words: cholesteryl ester • lipoprotein subspecies • HDL • VLDL • dyslipoproteinemia
This article has been cited by other articles:
 |
|
 |
|
  M. J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur. Heart J., October 12, 2009; (2009) ehp399v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Catalano, Z. Julia, E. Frisdal, B. Vedie, N. Fournier, W. Le Goff, M. J. Chapman, and M. Guerin Torcetrapib Differentially Modulates the Biological Activities of HDL2 and HDL3 Particles in the Reverse Cholesterol Transport Pathway Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 268 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kourimate, C. Le May, C. Langhi, A. L. Jarnoux, K. Ouguerram, Y. Zair, P. Nguyen, M. Krempf, B. Cariou, and P. Costet Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9 J. Biol. Chem., April 11, 2008; 283(15): 9666 - 9673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Steiner Atherosclerosis in type 2 diabetes: a role for fibrate therapy? Diabetes and Vascular Disease Research, December 1, 2007; 4(4): 368 - 374. [Abstract] [PDF]
|
|
|
|
 |
|
 C. C. van der Hoogt, W. de Haan, M. Westerterp, M. Hoekstra, G. M. Dallinga-Thie, J. A. Romijn, H. M. G. Princen, J. W. Jukema, L. M. Havekes, and P. C. N. Rensen Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression J. Lipid Res., August 1, 2007; 48(8): 1763 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Rosenson, D. A. Wolff, A. L. Huskin, I. B. Helenowski, and A. W. Rademaker Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome Diabetes Care, August 1, 2007; 30(8): 1945 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C.N. Rensen and L. M. Havekes Cholesteryl Ester Transfer Protein Inhibition: Effect on Reverse Cholesterol Transport? Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 681 - 684. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rizzo and K. Berneis Low-density lipoprotein size and cardiovascular risk assessment QJM, January 1, 2006; 99(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J. Chapman Review: Fibrates: therapeutic review The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 11 - 19. [Abstract] [PDF]
|
|
|
|
|
|
R. M. Krauss Lipids and Lipoproteins in Patients With Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1496 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Sacks and H. Campos Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4525 - 4532. [Full Text] [PDF]
|
|
|
|
|
|
M. Guerin, W. Le Goff, E. Frisdal, S. Schneider, D. Milosavljevic, E. Bruckert, and M. J. Chapman Action of Ciprofibrate in Type IIB Hyperlipoproteinemia: Modulation of the Atherogenic Lipoprotein Phenotype and Stimulation of High-Density Lipoprotein-Mediated Cellular Cholesterol Efflux J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3738 - 3746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. A. M. Jonkers, A. H. M. Smelt, H. Hattori, L. M. Scheek, T. van Gent, F. H. A. F. de Man, A. van der Laarse, and A. van Tol Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy J. Lipid Res., August 1, 2003; 44(8): 1462 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Watts, P. H. R. Barrett, J. Ji, A. P. Serone, D. C. Chan, K. D. Croft, F. Loehrer, and A. G. Johnson Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome Diabetes, March 1, 2003; 52(3): 803 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Winkler, C. Abletshauser, M. M. Hoffmann, I. Friedrich, M. W. Baumstark, H. Wieland, and W. Marz Effect of Fluvastatin Slow-Release on Low Density Lipoprotein (LDL) Subfractions in Patients with Type 2 Diabetes Mellitus: Baseline LDL Profile Determines Specific Mode of Action J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5485 - 5490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guerin, P. Egger, W. Le Goff, C. Soudant, R. Dupuis, and M. J. Chapman Atorvastatin Reduces Postprandial Accumulation and Cholesteryl Ester Transfer Protein-Mediated Remodeling of Triglyceride-Rich Lipoprotein Subspecies in Type IIB Hyperlipidemia J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4991 - 5000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Sniderman, T. Scantlebury, and K. Cianflone Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus Ann Intern Med, September 18, 2001; 135(6): 447 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Marz, H. Scharnagl, C. Abletshauser, M. M. Hoffmann, A. Berg, J. Keul, H. Wieland, and M. W. Baumstark Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype Circulation, April 17, 2001; 103(15): 1942 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sugano, S. Sawada, K. Tsuchida, N. Makino, and M. Kamada Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody J. Lipid Res., January 1, 2000; 41(1): 126 - 133. [Abstract] [Full Text]
|
|
|
|
|
|
M. Guerin, T. S. Lassel, W. Le Goff, M. Farnier, and M. J. Chapman Action of Atorvastatin in Combined Hyperlipidemia : Preferential Reduction of Cholesteryl Ester Transfer From HDL to VLDL1 Particles Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 189 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rubenfire Update in Cardiology Ann Intern Med, September 7, 1999; 131(5): 356 - 362. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lamarche, A. Tchernof, P. Mauriege, B. Cantin, G. R. Dagenais, P. J. Lupien, and J.-P. Despres Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart Disease JAMA, June 24, 1998; 279(24): 1955 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sugano, N. Makino, S. Sawada, S. Otsuka, M. Watanabe, H. Okamoto, M. Kamada, and A. Mizushima Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits J. Biol. Chem., February 27, 1998; 273(9): 5033 - 5036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Lassel, M. Guerin, S. Auboiron, M. J. Chapman, and B. Guy-Grand Preferential Cholesteryl Ester Acceptors Among Triglyceride-Rich Lipoproteins During Alimentary Lipemia in Normolipidemic Subjects Arterioscler Thromb Vasc Biol, January 1, 1998; 18(1): 65 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Packard and J. Shepherd Lipoprotein Heterogeneity and Apolipoprotein B Metabolism Arterioscler Thromb Vasc Biol, December 1, 1997; 17(12): 3542 - 3556. [Abstract] [Full Text]
|
|
|
|
|
|
M. Ayaori, T. Ishikawa, H. Yoshida, M. Suzukawa, M. Nishiwaki, H. Shige, T. Ito, K. Nakajima, K. Higashi, A. Yonemura, et al. Beneficial Effects of Alcohol Withdrawal on LDL Particle Size Distribution and Oxidative Susceptibility in Subjects With Alcohol-Induced Hypertriglyceridemia Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2540 - 2547. [Abstract] [Full Text]
|
|